PD-1 checkpoint inhibitors have been commercially available only since 2014, & PD-1 research with other immunotherapy modalities has only recently begun…
Targeted COMBO therapy regimens represent NEW innovations, & Roswell’s aDC1 technology is relatively new as a combo agent in clinical trials.
Fact ✅️: NWBO’s IP portfolio includes more than one pipeline product in active clinical development. For example, the aDC1 platform that NWBO licensed from Roswell Park in New York has reached PII in combo with Merck’s pembrolizumab. NEXT GEN COMBOS will make some significant waves going forward!
Merck is only one example, but the industry overall is trending toward combo research to enhance efficacy & reduce toxicity for patients.
Market Data 
Markets 
AI
